KYMR
Kymera Therapeutics, Inc.
Key Financials
Net Income
$-311351000
↓ 39.1%
Revenue
$39.2M
↓ 16.7%
Operating Income
$-349399000
↓ 33.5%
EPS (Diluted)
$-3.69
↓ 23.8%
Total Assets
$1.7B
↑ 78.2%
Total Liabilities
$163.1M
↑ 14.6%
Cash & Equivalents
$357.0M
↑ 196.9%
Shareholders' Equity
$1.6B
↑ 89.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4/A | 7/2/2026 | View on SEC |
| 144 | 7/2/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 144 | 6/30/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KYMR |
| Company Name | Kymera Therapeutics, Inc. |
| CIK | 1815442 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-285-5314 |